Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

BACKGROUND: Afatinib is one of the standard treatments for patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the use of afatinib in patients with poor performance status (PS ≥ 2) are limited. This study aimed to retrospectively review...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chiao-En, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Hsu, Ping-Chih, Chang, John Wen-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314552/
https://www.ncbi.nlm.nih.gov/pubmed/34315431
http://dx.doi.org/10.1186/s12885-021-08587-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314552/
https://www.ncbi.nlm.nih.gov/pubmed/34315431
http://dx.doi.org/10.1186/s12885-021-08587-w

Ejemplares similares